about
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.Improved survival with MEK inhibition in BRAF-mutated melanomaIpilimumab: from preclinical development to future clinical perspectives in melanoma.A positive antinuclear antibody test predicts for a poor response to initial steroid therapy in adults with idiopathic thrombocytopenic purpura.Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.Paclitaxel as neoadjuvant therapy for high grade angiosarcoma of the spleen: a brief report and literature review.Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced MelanomaEfficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trialLeiomyosarcoma of the head and neck: a population-based analysis.Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC studyPlasma angiopoietin 2 concentrations are related to impaired lung function and organ failure in a clinical cohort receiving high-dose interleukin 2 therapy.Melanoma cells undergo aggressive coalescence in a 3D Matrigel model that is repressed by anti-CD44.Jordan palliative care initiative: a WHO Demonstration Project.Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial.Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.Epigenetic silencing of the human NOS2 gene: rethinking the role of nitric oxide in human macrophage inflammatory responses.Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma.Imatinib Dosing in Gastrointestinal Stromal Tumors (GISTs): When, How Much, and How Long?Pembrolizumab Therapy Triggering an Exacerbation of Preexisting Autoimmune Disease: A Report of 2 Patient CasesA phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas.Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.Quantitative computed tomography determined regional lung mechanics in normal nonsmokers, normal smokers and metastatic sarcoma subjects.TAZ and YAP are frequently activated oncoproteins in sarcomas.Pityriasis lichenoides chronica-like drug eruption developing during pembrolizumab treatment for metastatic melanomaKeratoacanthoma-appearing melanoma metastases in a patient receiving pembrolizumab therapy.Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.Redox active metals and H2O2 mediate the increased efficacy of pharmacological ascorbate in combination with gemcitabine or radiation in pre-clinical sarcoma models.SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors.The feasibility of using intravenous fentanyl as sublingual drops in the treatment of incidental pain in patients with cancer.Cord blood stem cell expansion is permissive to epigenetic regulation and environmental cues.Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM.Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study.Diagnosis of poorly differentiated thyroid cancer with radioiodine scanning after thyrotropin alfa stimulation.Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.Insights into the Proteome of Gastrointestinal Stromal Tumors-Derived Exosomes Reveals New Potential Diagnostic Biomarkers.Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.Quality-of-life outcomes in patients with advanced melanoma: A review of the literature.
P50
Q27853021-D5278ECA-C0FD-47C6-8C48-8DBF999CAFFDQ29620663-487A20EA-9D6E-45B2-8CF5-6929090785A6Q30240751-0D4F628C-AB00-4C89-98F9-839F8CEF2F1CQ33378599-F8EE4A77-CC5B-40AB-8FC8-078D6E1DA70FQ33408040-5B339696-C534-4FCA-9DC7-A23A2472F366Q33416734-B1EA3576-6B44-4B3D-85F5-907E08C69A34Q33442984-FB2C7788-BB2B-4D43-A145-187360B1B169Q34207210-87C1C31D-C401-44B5-8742-7E6246DE03B2Q34478015-1DADB366-0BA5-4848-9B34-2FF4E8A1071AQ34848294-50F295EA-F703-44EB-B7D9-7D91718507DEQ35133052-FE2C5439-4492-46A0-AB81-310BA7FFC4D4Q35611877-1A6C4D55-8200-4C55-BFF8-5F32739F1B43Q35742907-33F60151-95D9-495A-9F13-3CFB18ABB790Q36298393-E599525C-91B8-4FC9-813F-DD3642DAE1B4Q36812033-4AECB294-356E-4AE8-AD31-A950E94503B3Q37350801-624FA16D-D1C8-45CA-9F09-ACAA8C7ADAC0Q37385677-DCBE9AD4-A85E-481E-81A0-59337E6BB0B6Q37456334-8DB8FDA1-91B4-4799-847B-E8007400B617Q37620142-13C43E91-8830-4013-8F0E-A45D1B3FC564Q38383826-13F802C8-F902-4BA3-9E0C-BE376C58A1F4Q38628209-7CB0AFAC-9265-44A0-9349-D9AC1FC0A81AQ39003398-5F9125FD-42B5-48AA-9351-C1EF6FF5E651Q40521748-7772629D-4B0A-4A58-B965-70D603BCC031Q40702544-E125801F-3F64-43CC-921A-280A5AD79944Q41153332-AC84185C-C532-4D12-A4BC-3E2D5E15CE6BQ41416961-BA01E821-53AA-468C-8CCA-421A813166ADQ41511001-7F3FA5C4-9D9B-4C90-A967-37043293E26CQ41889866-D5CB3EA3-05F9-466D-9F04-9AF518F7E783Q41923731-7ED6E673-1E9E-435F-B36D-CC3DFD6D9A72Q42654817-E3E56680-8340-4852-9FAA-9C15E97F5CF1Q43375854-CDA22874-DB64-4A49-8427-DDA9D8FC993DQ45976784-C8C666F0-481F-45CA-9F31-89BEBEF751D7Q45980641-6360CC8A-309B-43DE-80C1-B87CC1B6806FQ46007260-31009276-9739-4341-A1D8-F290306616D1Q46071137-F428DDF3-EEE1-49AB-A799-15319FB27ABDQ46361435-DE1AEAFF-6CB8-41A9-984B-181B31ED2F02Q46688699-F2F84447-7072-4A89-BEA0-68801A5632FFQ47292108-1B72BD73-A849-46A9-ADC6-E9EF80B5C8A0Q47556374-093C0B5A-B666-440E-9E65-37AEAA43AA48Q48285831-F5338D32-9E7E-4134-9B03-3D7EDCEBF664
P50
description
researcher, ORCID id # 0000-0003-4663-6824
@en
wetenschapper
@nl
name
M Milhem
@ast
M Milhem
@en
M Milhem
@es
M Milhem
@nl
type
label
M Milhem
@ast
M Milhem
@en
M Milhem
@es
M Milhem
@nl
prefLabel
M Milhem
@ast
M Milhem
@en
M Milhem
@es
M Milhem
@nl
P106
P1153
6508228025
P31
P496
0000-0003-4663-6824